Merck & Co. Inc.: Communication lessons from the withdrawal of Vioxx

Journal of Business Strategy

Volumn 27, Issue 4, 2006, Pages 11-22

  O'Rourke IV, James S ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746148930     PISSN: 02756668     EISSN: None     Source Type: Journal    
DOI: 10.1108/02756660610677092     Document Type: Article

References (27)

1. Abboud, L. and Anand, G. (2004), "Recall of Merck's pain drug sparks hunt for alternatives: just how safe is Celebrex?", The Wall Street Journal, October 1.
2. Anon (2000), "FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the products", available at: www.fda/gov/topics/news/2004/NEW01122.html (accessed September 30, 2005).
3. Anon (2004a), "FDA accused of silencing Vioxx warnings", Associated Press, October 8.
4. Anon (2004b), "Pfizer ordered to pull Viagra commercials", Associated Press, November 16.
5. Anon (2005), "Major victory for Merck in NJ Vioxx trial", Associated Press, November 3.
6. (The) Associated Press (2004), "Shares close mixed as Merck pulls down blue chips", The New York Times, October 1.
7. Barrett, A. (2005), "The pain is just beginning: why the Vioxx debacle will hobble Merck for years to come", Business Week, September 5, pp. 40-1.
8. Berenson, A. (2005), "Judge declares mistrial in Merck Vioxx trial because of hung jury", The New York Times, p. 1.
9. Feder, B.J. (2004), "Lawyers organizing for mass suits over Vioxx", The New York Times, November 5.
10. Fredenheim, M. (2004), "A blow to efforts to close in on rivals", The New York Times, October 1.
11. Harris, G. (2004), "Study says drug's dangers were apparent years ago", The New York Times, November 5.
12. Henderson, D. (2004), "Vioxx withdrawal causes concern about FDA", The Seattle Post-Intelligencer, October 2.
13. Hensley, S. (2004), "Merck faces US criminal probe over Vioxx drug", The Wall Street Journal, November 9.
14. Hensley, S. and Palmer, K. (2004), "Merck plunge tests investors", The Wall Street Journal, October 1.
15. Herskovits, B. (1995), "Hefty Merck verdict spurs firms to rethink DTC efforts", PR Week, August 29, p. 1.
16. Jenkins, H.W. Jr (2004), "Was withdrawing Vioxx the 'right thing to do'?", The Wall Street Journal, November 10.
17. Kolata, G. (2004), "A widely used arthritis drug is withdrawn", The New York Times, October 1.
18. Martinez, B. (2005), "Merck will slash work force by 11 percent", The Wall Street Journal, November 29, pp. A3-A8.
19. Martinez, B. and Matthews, A.W. (2004), "E-mails suggest Merck knew Vioxx's dangers at early stage", The Wall Street Journal, November 1.
20. Martinez, B., Mathews, A.W., Lublin, J.S. and Winslow, R. (2004), "Merck pulls Vioxx from market after link to heart problems", The Wall Street Journal, October 1.
21. Pollack, A. (2004a), "Justice Department and SEC investigating Merck drug", The New York Times, November 9.
22. Pollack, A. (2004b), "New scrutiny of drugs in Vioxx's family", The New York Times, October 4.
23. Simons, J. and Stipp, D. (2004), "Will Merck survive Vioxx?", Fortune Magazine, November 1.
24. Steinberg, B. and Vranica, S. (2004), "Not such a 'beautiful morning'", The Wall Street Journal, October 1.
25. Steyer, R. (2005), "Merck names Clark CEO", TheStreet.com, available at: www.thestreet.com/stocks/robertsteyer/10221884.html (accessed December 21, 2005).
26. Topol, E. (2004), "Good riddance to a bad drug", The New York Times, October 2.
27. (The) Wall Street Journal (2004), "A Vioxx elegy", The Wall Street Journal, October 1.